Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Revenue by Segment

Period Ending	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018
Royalties	522.62M	482.00M	468.82M	447.87M	431.79M	416.91M	390.51M	360.48M
Royalties Growth	21.04%	15.61%	20.05%	24.24%	36.16%	50.98%	65.06%	76.79%
Product Sales	303.73M	303.64M	298.64M	300.85M	282.42M	257.27M	229.68M	191.03M
Product Sales Growth	7.55%	18.02%	30.02%	57.49%	79.98%	113.44%	119.59%	83.29%
Revenues Under Collaborative Agreements	121.00M	87.67M	95.53M	80.53M	66.50M	99.47M	84.79M	108.61M
Revenues Under Collaborative Agreements Growth	81.95%	-11.86%	12.67%	-25.85%	-37.60%	9.55%	-34.97%	-19.66%

Operating Expense Breakdown

Period Ending	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018
Cost of Sales	169.66M	175.06M	185.52M	192.36M	182.18M	174.68M	158.55M	139.30M
Cost of Sales Growth	-6.87%	0.22%	17.01%	38.09%	53.39%	94.00%	100.40%	71.11%
Selling, General, and Administrative	149.69M	143.72M	146.96M	149.18M	149.32M	148.52M	167.05M	143.53M
Selling, General, and Administrative Growth	0.25%	-3.23%	-12.03%	3.94%	24.90%	51.16%	214.61%	185.21%
Research and Development	79.94M	78.81M	77.50M	76.36M	77.59M	76.98M	72.73M	66.61M
Research and Development Growth	3.03%	2.38%	6.55%	14.65%	43.30%	67.60%	88.84%	86.72%
Amortization	71.05M	73.63M	73.70M	73.77M	60.56M	67.42M	60.98M	43.15M
Amortization Growth	17.31%	9.22%	20.85%	70.98%	56.92%	491.20%	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.